Teva Blasts FTC's Position On Pay-For-Delay
In response to Federal Trade Commission Chairman Jon Leibowitz's claims that banning "pay-for-delay" patent settlements between generics and branded drugmakers would save consumers $3.5 billion a year, leading generics maker Teva...To view the full article, register now.
Already a subscriber? Click here to view full article